|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Mr. William H. Lewis J.D.||Pres, CEO & Chairman||1,24M||N/A||1969|
|Mr. Roger Adsett||Chief Operating Officer||773,14k||N/A||1969|
|Ms. Christine A. Pellizzari J.D.||Chief Legal Officer & Corp. Sec.||730,61k||N/A||1968|
|Dr. Paul D. Streck||Advisor||733,67k||N/A||1964|
|Ms. Sara M. Bonstein||Chief Financial Officer||N/A||N/A||1981|
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
El ISS Governance QualityScore de Insmed Incorporated, a día 3 de diciembre de 2019, es 7. Las puntuaciones base son Auditoría: 2; Tablero: 6; Derechos de los accionistas: 10; Compensación: 5.